Janssen&Janssen schreef op 19 juni 2022 22:43:
Ondanks dat pharming niet altijd helder communiceert omtrent gang van zaken hebben ze afgelopen week wel weer een mooie samenwerking in gang gezet om Leniolisib breder uit te rollen & kenbaar te maken.
8th June 2022
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH PHARMING GROUP FOR EXPANDED ACCESS PROGRAM FOR LENIOLISIB
WEP Clinical (WEP) is pleased to announce our partnership with Pharming Group N.V. (“Pharming” EURONEXT Amsterdam: PHARM/Nasdaq: PHAR), a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, to make rare disease investigational drug, leniolisib, available through an Expanded Access Program (EAP).
Leniolisib is being developed to treat Activated PI3K Delta Syndrome (APDS). APDS is defined as a rare, genetic, primary immunodeficiency disease with a prevalence of 1 – 2 per 1,000,000 of population and characterised by increased susceptibility to recurrent and/or severe bacterial and viral infections, chronic benign lymphoproliferation, and/or autoimmune disease and premature mortality. Leniolisib was recently in-licensed by Pharming from Novartis and is being studied in a registration-enabling Phase II/III trial.
Together, Pharming and WEP transitioned patients from the previous Novartis-run EAP into the Pharming EAP, managed by WEP, to allow patients to continue accessing the treatment.
The objective of this EAP is to provide leniolisib to eligible APDS patients in need of treatment who are otherwise unable to participate in a clinical study or for whom access is otherwise not available through marketed product in their country, and to provide physicians with early access and experience with leniolisib.
Jas Khera, Managing Director of WEP, said:
“It is great to be working with Pharming to support making this drug available to patients diagnosed with APDS. This EAP will ensure that patients with a high unmet need have a secure and compliant supply of this treatment option available to them, which is in-keeping with WEP’s and Pharming’s shared goal of broadening access to critical, innovative medicines worldwide.”
Health care professionals can inquire for more details about leniolisib and the EAP by emailing WEP.
About WEP
Established in 2008, WEP is a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available. We have offices located in London, United Kingdom; RTP North Carolina, United States; Lisbon, Portugal; and Dublin, Ireland and possess all the necessary licenses allowing us to meet drug access and distribution needs across all regions, worldwide. We are passionate about helping those in need. For more information, please visit
www.wepclinical.com.www.wepclinical.com/wep-clinical-anno...